Zydus Lifesciences liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.91×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.27×	1.27×	1.89×	2.14×	1.81×
0.91×	0.91×	1.45×	1.49×	1.19×
6,631	6,631	5,678	666	1,107
4,194	4,194	8,005	6,080	4,482

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZYDUSLIFE₹1,184.40

Zydus Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA TORNTPHARM DIVISLAB MAXHEALTH APOLLOHOSP AUROPHARMAMcap ₹1.19L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.91
Current Ratio	1.81	2.14	1.89	1.27	1.27
Quick Ratio	1.19	1.49	1.45	0.91	0.91
Cash, Equiv & ST Investments	1,107.1	665.5	5,677.9	6,631.0	6,631.0
Working Capital	4,481.5	6,080.1	8,004.5	4,194.2	4,194.2

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.